1. Participation in any other clinical trial of an experimental treatment for COVID-19 <br/ >2.Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 is prohibited < 24 hours prior to study medication initiation <br/ >3.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN) <br/ >4.Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >5.Pregnant women or women who are breastfeeding <br/ >6.Immunocompromised patients taking medication upon screening <br/ >7.Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment <br/ >

1. Participation in any other clinical trial of an experimental treatment for COVID-19 <br/ >2.Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 is prohibited < 24 hours prior to study medication initiation <br/ >3.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN) <br/ >4.Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >5.Pregnant women or women who are breastfeeding <br/ >6.Immunocompromised patients taking medication upon screening <br/ >7.Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment <br/ >

N/A

N/A

1. Participation in any other clinical trial of an experimental treatment for COVID-19 <br/ >2.Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 is prohibited < 24 hours prior to study medication initiation <br/ >3.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN) <br/ >4.Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >5.Pregnant women or women who are breastfeeding <br/ >6.Immunocompromised patients taking medication upon screening <br/ >7.Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment <br/ >

1. Participation in any other clinical trial of an experimental treatment for COVID-19 <br/ >2.Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 is prohibited < 24 hours prior to study medication initiation <br/ >3.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN) <br/ >4.Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) <br/ >5.Pregnant women or women who are breastfeeding <br/ >6.Immunocompromised patients taking medication upon screening <br/ >7.Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment <br/ >